Drug Profile
TXA 302
Alternative Names: TXA-302Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator TarixCVM
- Developer Constant Therapeutics
- Class Angiotensins; Cardiovascular therapies; Peptides; Vascular disorder therapies
- Mechanism of Action Haematopoietic cell growth factor stimulants; Proto-oncogene protein c-mas-1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Metabolic disorders; Stroke
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Cardiovascular disorders in USA (SC) (Constant Therapeutics pipeline, September 2023)
- 13 Sep 2023 Discontinued - Preclinical for Metabolic disorders in USA (SC) (Constant Therapeutics pipeline, September 2023)
- 13 Sep 2023 Discontinued - Preclinical for Stroke in USA (SC) (Constant Therapeutics pipeline, September 2023)